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Background: Various definitions of hyperkalaemia have been used in clinical research, and data from routine
clinical practice on its incidence are sparse. We aimed to establish the incidence of hyperkalaemia in patients with
newly diagnosed heart failure in the UK general population using different definitions for the condition.
Methods: We conducted a large retrospective cohort study using data from The Health Improvement Network
primary care database. Patients with newly diagnosed heart failure (N = 19,194) were identified and followed until
the first occurrence of hyperkalaemia. Different serum potassium (K+) thresholds were evaluated as possible
definitions for hyperkalaemia, and incidence rates (IRs) calculated using a final operational definition both overall
and among patient sub-groups.
Results: IRs of hyperkalaemia ranged from 0.92–7.93 per 100 person-years according to the definition. Based on
considerable differences in the serum K+ normal range used between practices, 2176 (11.3 %) individuals were
identified with a record of hyperkalaemia using our operational definition of a proportional increase of ≥10 %
above the upper bound of the normal range: IR 2.90 per 100 person-years (95 % CI 2.78–3.02) over a mean follow-
up of 3.91 years. Incidence rates were higher in older patients, and in those with diabetes or renal impairment.
Conclusions: Hyperkalaemia is a common finding in heart failure patients in primary care, but its incidence can
vary nearly ten-fold depending on its definition. Since assessment of hyperkalaemia risk is essential for therapeutic
decision making in heart failure patients, this finding warrants consideration in future epidemiological studies.
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Hyperkalaemia is a common condition in patients with
heart failure with most cases either asymptomatic or asso-
ciated with mild, non-specific symptoms, yet more severe
clinical manifestations can occur without warning [1].
Population based time-series analyses have demonstrated
significant increases in rates of hospitalisation and
mortality from hyperkalaemia in real-world clinical
practice, correlating with the more widespread use of* Correspondence: alexander.michel@bayer.com
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system (RAAS) [2, 3]. These medications – either alone or
in combination – are effective therapies for patients with
heart failure, yet it is important to assess the risk of hyper-
kalaemia before initiating treatment because many of
these patients already have impaired potassium excretion
placing them at increased risk of hyperkalaemia, in par-
ticular the elderly and those with renal impairment or dia-
betes [4–6]. Incorporating the risk of hyperkalaemia into
therapeutic decision making in heart failure patients
depends upon having a precise definition for an episode of
the condition, yet at present there is no consensusarticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Martín-Pérez et al. BMC Family Practice  (2016) 17:51 Page 2 of 8regarding the most appropriate threshold of serum potas-
sium (K+) to apply – various thresholds [7–11] or other
operational definitions [12] for hyperkalaemia have been
used in previous studies.
Current data on the incidence of hyperkalaemia in pa-
tients with heart failure come mainly from clinical trial
populations treated with RAAS antagonists [7, 12, 13],
which may not reflect the actual burden of hyperkalaemia
in clinical practice. Patients entering clinical trials are se-
lected carefully, excluding those who are considered to be
at highest risk for potential adverse reactions with use of
the study medication. Population-based data from routine
clinical practice focusing on the incidence of hyperkalae-
mia are sparse, yet are potentially attainable through the
use of large population-based databases of anonymized
electronic medical records (EMRs). The Health Improve-
ment Network (THIN) [14] is one of several such data-
bases arising from general practices throughout the
United Kingdom (UK), which are increasingly being used
for pharmacoepidemiological research. They enable long-
term follow-up of observational cohorts, and are able to
provide large samples that are often representative of the
target population. This study aimed to i) estimate the inci-
dence of hyperkalaemia in a large population-based cohort
of incident heart failure patients in THIN using different
definitions of the outcome, and ii) using a final operational
definition for hyperkalaemia, estimate the incidence of
hyperkalaemia both overall and among patients sub-
groups. The study protocol was reviewed and approved by
the scientific review committee (SRC, reference number
13–030) for THIN [15].
Methods
Data source
A retrospective cohort study was performed using THIN.
The database is representative of the UK population with
regards to age, sex and geographic distribution, and has
been validated for use in pharmacoepidemiological re-
search [16, 17]. In the UK, the National Health Service
provides free universal health care for all residents. Pri-
mary care practitioners (PCPs) are the first point of con-
tact for patients, acting as a gatekeeper to secondary care;
details of consultations in secondary care are communi-
cated back to primary care and patients’ medical records
are updated retrospectively. In addition, chronic disease in
the UK is largely managed in the primary care setting,
making THIN an excellent data source to evaluate the
occurrence and risk factors for clinical outcomes in
patients with heart failure.
Study population
A previously identified cohort of patients aged 1–89 years
between 1 January 2000 and 31 December 2005 with a first
ever diagnosis of heart failure (inception cohort) and noprevious diagnosis of cancer comprised our initial study
cohort (N = 19,194); there were only 12 patients under
18 years old. Patients were required to have been registered
for at least 1 year with their PCP and to have at least 1 year
of computerized prescription history. At the time of diag-
nosis, approximately half (54.1 %) of the patients were
ambulatory and managed by the PCP only, while 27.3 %
were referred to a consultant and 18.6 % had a related
hospitalization [18]. Among a random sample of the heart
failure cohort (n = 200), 84 % had the diagnosis of incident
heart failure validated by their PCP (Ruigómez A, unpub-
lished data). All patients in the study cohort were followed
from the start date (date of first recorded diagnosis of heart
failure) until the earliest of the following: occurrence of
hyperkalaemia, reaching 90 years of age, death, cancer or
end of the study period (December 2011).
Hyperkalaemia case ascertainment and definition
Potential cases of hyperkalaemia were identified through
an initial computer search for abnormal serum K+ values
or the Read codes ‘Hyperkalaemia’ and ‘Raised serum po-
tassium level’ during follow-up. Guidelines define hyper-
kalaemia as a value of serum potassium (K+) >5.5 mmol
[19, 20]. Recent clinical trials have therefore used fixed
serum K+ thresholds to define hyperkalaemia, varying
between ≥5.5 mmol/L and ≥6 mmol/L [7, 13, 21]. How-
ever, due to considerable differences in the upper bound
of serum K+ normal range between practices contributing
to THIN (range: 4.4 to 5.7 mmol/L), the former definition
was not appropriate for our study. Thus, we tested several
serum K+ thresholds to define hyperkalaemia, in order to
analyze the absolute impact on estimates of outcome
frequency and on the occurrence of a major clinical event
(case-fatality). A summary of this sensitivity exercise is
shown in Table 1.
Exclusion criteria for all tested definitions were: serum
K+ levels that returned to normal range within 3 days
following the initial measurement that qualified as
hyperkalaemia (possible pseudohyperkalaemia), and high
values of serum K+ (≥10 mmol/L) considered as outliers.
Of the six definitions tested, two were based on fixed
absolute values irrespective of normal values applied in
different laboratories; only 6 % of heart failure patients
had values of K+ of ≥6 mmol/L, while 17 % had values
equal or ≥5.5 mmol/L. In three definitions we used
different proportional increases above the upper limit of
the normal serum K+ value used by the respective refer-
ence laboratory, and for the remaining definition, any
value above the upper range of normal bound for the
corresponding practice was used to define hyperkalaemia
(Table 1).
Among the six hyperkalaemia definitions tested, we de-
cided to use a proportional increase above the referral la-
boratories’ upper bound of normal range and reject using
Table 1 Number of HF patients with hyperkalaemia and incidence rates according to different hyperkalaemia definitions
Hyperkalemia definition Patients identified with serum K+
qualifying valuea




30-day case fatality 1-year case fatality
Serum K+ >the upper limitb 5123 26.7 7.93 (7.72–8.14) 140 (2.7 %) 899 (17.5 %)
Serum K+ ≥5.5 mmol/L 3265 17.0 4.55 (4.40–4.71) 118 (3.6 %) 647 (19.8 %)
Serum K+ ≥10 % upper limitb 2155 11.2 2.87 (2.75–2.99) 78 (3.6 %) 460 (21.3 %)
Serum K+ >10 % upper limitb 1909 9.9 2.52 (2.41–2.63) 80 (4.2 %) 437 (22.9 %)
Serum K+ ≥6 mmol/L 1097 5.7 1.40 (1.32–1.49) 65 (5.9 %) 294 (26.8 %)
Serum K+ ≥20 % upper limitb 724 3.8 0.92 (0.85–0.98) 47 (6.5 %) 198 (27.3 %)
aNumber of patients with a hyperkalaemia episode identified in the follow-up
bUpper bound of normal range used in the corresponding practice
HF heart failure, IR incidence rate
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threshold (e.g. ≥5.5 mmol/L or ≥6 mmol/L) to define
hyperkalaemia as in previously published studies [7, 8, 22].
Our decision was based on the results of our sensitivity
analysis (Table 1), which showed considerable variation in
hyperkalaemia incidence rates according to the definition
used and because it accounted for the variation in the nor-
mal range of serum K+ values between different practice
referral laboratories in THIN. The least restrictive defin-
ition of hyperkalaemia (value of serum K+ above the upper
bound of normal value of the referral laboratory) classified
more than a quarter of newly diagnosed heart failure pa-
tients as cases of hyperkalaemia, which might include
non-clinically important cases, while the most stringent
definition (≥20 % above the upper bound of normal range)
classified the smallest percentage of heart failure patients
as hyperkalaemia cases and could possibly have included
only the most severe cases. Therefore, we chose to define
an episode of hyperkalaemia as a recorded serum K+ value
of ≥10 % above the upper bound of the normal range
reported by the practice’s referral laboratory. In practice,
our definition is approximately equivalent to adding 10 %
above the range of 5–5.5 mmol/L, the upper limit of
normal range in 96 % of practices in THIN. Additionally,
in the absence of a recorded qualifying serum K+ value,
patients with a recorded Read code for hyperkalaemia
together with a referral to a specialist or hospital admis-
sion were also considered to be cases of hyperkalaemia in
our final operational definition. This occurred in less than
1 % of our final set of hyperkalaemia cases. The date of
first hyperkalaemia episode recorded during the follow-up
was considered to be the outcome date.
Data collection
Information on patient demographics, comorbidities, and
healthcare utilization was extracted from THIN. Comor-
bidities included diabetes, renal impairment (identified
using recorded creatinine values) and prior hyperkalaemia
(identified using the same final operational definition de-
scribed previously). We used the Modification of Diet in
Renal Disease equation to calculate estimated glomerularfiltration rate (eGFR) and to define renal impairment as
eGFR <60 mL/min/1.73 m2. Healthcare utilization data
comprised records of referrals and hospitalizations at the
time of heart failure diagnosis.
Statistical analysis
Using each of the six hyperkalaemia definitions, the inci-
dence of hyperkalaemia was calculated as the number of
incident cases per 100 person-years. Using our final se-
lected operational definition of hyperkalaemia (serum K+
≥10 % above upper bound of normal range), we esti-
mated incidence rates with 95 % confidence intervals
(CIs) both overall and stratified by age, sex, referral/
hospitalization status at heart failure diagnosis (as a
proxy for heart failure severity), diabetes, prior hyperka-
laemia, and degree of renal impairment. Kaplan–Meier
survival curves by age, sex, diabetes and renal function
were produced and compared using the log-rank test.
We also calculated 30-day and 1-year case-fatality rates
using each of the six hyperkalaemia definitions. Statis-
tical analyses were performed using Stata version 12.0
(StataCorp LP, College Station, TX, USA).
Results and discussion
Among the cohort of 19,194 incident heart failure pa-
tients, 15,888 (83 %) patients had at least one laboratory
value of serum K+ recorded after their first ever diagno-
sis of heart failure. Estimated incidence rates of hyperka-
laemia varied from 0.92 to 7.93 per 100 person-years
according to the definition of hyperkalaemia evaluated
(Table 1). Applying our final operational definition of
hyperkalaemia (K+ ≥10 % above upper bound of normal
range), we identified 2,278 (12 %) patients with at least
one qualifying value during follow-up. Among these,
there were 38 patients with extremely high values that
were considered computer entry errors, and 85 patients
with a normal serum K+ value within 3 days following
the first K+ measurement qualifying for hyperkalaemia
(possible pseudohyperkalaemia); none of these patients
were retained as cases of hyperkalaemia. We also identi-
fied 173 patients with a Read code for hyperkalaemia
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cases fulfilled the referral/hospitalization criteria required
for inclusion as a hyperkalaemia case. In total, 2,176
patients (11.3 %) were considered to have an episode of
hyperkalaemia over a mean follow-up period of 3.9 years
(standard deviation ± 3.21 years), resulting in an overall
incidence rate of 2.90 per 100 person-years, 95 % CI:
2.78–3.02. The mean age among cases of hyperkalaemia
was 75 years (range: 23–89 years). For hyperkalaemia
cases, short-term (30-day) and long-term (1-year) case-
fatality rates increased within increasingly stringent hyper-
kalaemia definition. Short-term case-fatality ranged from
2.7 to 6.5 % while long-term case-fatality ranged from 17.5
to 27.3 %.
Figure 1 shows the incidence rate of hyperkalaemia by
age and sex strata. Overall incidence was slightly higher
in men (3.10, 95 % CI: 2.93–3.27 per 100 person-years)
than women (2.67, 95 % CI: 2.50–2.84 per 100 person-
years), and increased with age. Over the entire follow-up
period, 87.1 % of hyperkalaemia cases had five or more
recorded serum K+ values after their heart failure diag-
nosis. Twenty percent of hyperkalaemia cases were
ascertained (using a qualifying serum K+ value) within
the first 6 months after the date of heart failure diagno-
sis. The number of recorded serum K+ values per pa-
tient, and the distribution of the time since heart failure
diagnosis and the first recorded occurrence of hyperka-
laemia, did not vary substantially according to whether
the patient had diabetes or renal impairment.
When we examined the incidence of hyperkalaemia
according to patient’s renal function, we found higher
incidence rates with declining eGFR: 2.47 per 100
person-years for patients with normal renal function
(eGFR ≥60 ml/min/1.73 m2) and 11.06 per 100 person-
years for those with eGFR <30 ml/min/1.73 m2 (Table 2).Fig. 1 Incidence rate of hyperkalaemia among newly diagnosed heart failuKaplan–Meier survival analysis showed the higher inci-
dence among patients with renal impairment to be rela-
tively constant over the duration of study (log-rank test,
p <0.001) (Fig. 2). A higher incidence rate of hyperka-
laemia was also found among patients with diabetes
(5.50 per 100 person-years) compared with patients
without diabetes (2.40 per 100 person-years) (Table 2).
The higher incidence among diabetics was also rela-
tively constant over the duration of the study (log-
rank test, p <0.001) (Fig. 3). The incidence of hyperka-
laemia also depended on heart failure severity at diagnosis
when using hospitalization status at heart failure diagnosis
as a rough proxy-measure. Nearly half (49.4 %) of the
heart failure patients who developed hyperkalemia during
follow-up were managed only by their PCP at the time of
initial heart failure diagnosis, while the others were
referred to a specialist (30.2 %) or were hospitalized
(20.4 %) at initial diagnosis. Corresponding hyperkalaemia
incidence rates (95 % CIs) during follow-up were 2.53
(2.38–2.68), 3.12 (2.89–3.37) and 3.84 (3.49–4.21),
respectively.
Few studies have evaluated the incidence of hyperkalae-
mia in clinical practice. In our large population-based co-
hort study in the UK, the incidence rate of hyperkalaemia
among newly diagnosed heart failure patients in real-life
clinical practice was found to be 2.90 per 100 person-
years, using a definition of serum K+ of ≥10 % above the
upper limit of normal range. Our study also has the nov-
elty of investigating the effects of differing diagnostic
thresholds on the resulting incidence rates in this patient
population, highlighting the importance of applying a
precise definition of the outcome. We found that the K+
threshold used to define hyperkalaemia had a significant
impact on incidence rate estimates – an almost 10-fold
difference was observed between the most restrictive andre patients by age and sex
Table 2 Incidence rate of hyperkalaemia in the HF cohort according to several potential risk factors
Cases N = 2176 Person-years IR per 100 person-years (95 % CI)
Sex
Male 1259 40,639 3.10 (2.93–3.27)
Female 917 34,403 2.67 (2.50–2.84)
Age at HF diagnosis (years)
20–49 49 2824 1.74 (1.31–2.30)
50–59 164 8355 1.96 (1.70–2.29)
60–69 500 17,836 2.80 (2.60–3.06)
70–79 961 30,329 3.17 (2.97–3.40)
≥80 502 15,698 3.20 (2.93–3.49)
Diabetes
No 1507 62,887 2.40 (2.28–2.52)
Yes 669 12,155 5.50 (5.10–5.94)
Renal impairment
No renal impairment (eGFR ≥60 ml/min/1.732) 656 26,594 2.47 (2.29–2.66)
eGFR 45–59 ml/min/1.732 497 14,392 3.45 (3.16–3.77)
eGFR 30–44 ml/min/1.732 332 5503 6.03 (5.42–6.72)
eGFR <30 ml/min/1.732 134 1211 11.06 (9.34–13.10)
No recorded eGFR 557 27,342 2.04 (1.87–2.21)
Hyperkalaemia prior to HF
No 1946 73,237 2.66 (2.54–2.78)
Yes 230 1805 12.74 (11.20–14.50)
Within 90 days before 51 363 14.05 (10.68–18.48)
Within 91–365 days before 84 511 16.45 (13.28–20.37)
Within >365 days before 95 931 10.20 (8.34–12.47)
CI confidence interval, eGFR estimated glomerular filtration rate, HF heart failure, PCP primary care practitioner
aIncludes the 2155 cases of hyperkalaemia identified based on having recorded serum K+ ≥10 % upper limit of normal and a further 21 cases of hyperkalaemia
identified using Read codes only but who also had a record of a referral or hospitalization
Fig. 2 Proportion of heart failure patients not developing hyperkalaemia during follow-up according to the degree of renal impairment at heart
failure diagnosis (Kaplan–Meier survival estimates). eGFR estimated glomerular filtration rate, HF heart failure
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Fig. 3 Proportion of heart failure patients not developing hyperkalaemia during follow-up according to diabetes status at heart failure diagnosis
(Kaplan–Meier survival estimates). HF heart failure
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7.93 per 100 person-years). We also showed increasing
case-fatality rates with increasingly more stringent hyper-
kalaemia definitions. In previous clinical studies, hyperka-
laemia has been defined as any value of serum K+ above
an absolute value. These studies have generally involved a
particular referral laboratory applying an absolute serum
K+ value to define hyperkalaemia [21, 22]. However, this
definition is not the most appropriate for studies of pa-
tients coming from different general practices, which use
different referral laboratories with their own normal range
of laboratory parameters, as in our study cohort, and we
considered this factor very meaningful when deciding
upon our final operational definition. Also, there is no
consensus concerning the serum K+ threshold to identify
hyperkalaemia cases, making it difficult to compare re-
ported incidence rates between studies. The most com-
monly used threshold to define hyperkalaemia is a serum
K+ value of >5.5–6.0 mmol/L [6–8, 13, 21, 23, 24]. Other
studies have used a lower serum K+ threshold, such as
5.0 mmol/l [9, 10] or 5.3 mmol/l [11], while some have
not used a specific serum K+ threshold, but used what the
investigator considered to be an important rise in serum
K+ level based on clinical criteria [12]. Furthermore, other
researchers have defined hyperkalaemia based only on
International Classification of Diseases codes either in the
general practice setting [25] or when diagnosed upon hos-
pital admission [2, 26]. In our study, we retained only 21
patients (1 %) as cases of hyperkalaemia based only on
Read codes but we further required them to have been
referred or hospitalized at that point.
Clinical manifestations of hyperkalaemia do not usually
occur at serum K+ values <5.5 mmol/L with severe hyper-
kalaemia usually considered as serum K+ ≥6.0 mmol/L[24]. The risk of potential hazards increase with increasing
serum K+ levels, with risks especially increased when serum
K+ levels are >7.5 mmol/L [6, 23]. Limiting case definitions
to include only severe cases of hyperkalaemia (≥6 mmol/L)
has been shown to significantly underestimate the risk of
hyperkalaemia [13]. Furthermore, available evidence regard-
ing the risk of hyperkalaemia in patients with heart failure
comes mainly from clinical trials investigating the efficacy
of RAAS antagonists as heart failure treatment, with re-
ported proportions ranging from 1.1 % when thresholds are
more restrictive [13] up to 13.4 % with less restrictive
thresholds [12, 13, 21]. It is also difficult to compare rates
between studies due to differences in the baseline charac-
teristics of the patients enrolled (e.g. age, severity of heart
failure, concomitant medications and comorbidities). Pa-
tients in clinical trials are also selected carefully, specifically
excluding those at a higher risk of experiencing potential
adverse events, and with intensive monitoring during
follow-up. Estimates from clinical trial settings might not
be comparable to those in clinical practice where estimates
as high as 24 and 36 % have been reported, albeit from
small study populations [3, 10]. Our findings are in line
with those from a recent multisite database study con-
ducted by Raebel et al. [27] involving ambulatory patients
with diabetes newly initiating a therapy with angiotensin-
converting enzyme (ACE) inhibitors, angiotensin receptor
blockers (ARBs) or spironolactone. The authors found that
the degree of restriction in hyperkalaemia definitions af-
fected incidence rates in a similar way as in our study. In a
retrospective analysis of data in the Studies of Left Ven-
tricular Dysfunction trials, de Denus et al. [13] also showed
the incidence of hyperkalaemia to vary substantially de-
pending on the serum K+ thresholds used to define a
hyperkalaemia episode.
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failure is critically important to prevent severe outcomes,
especially among patients at high risk. In line with previ-
ous studies that have documented advanced age [9, 12],
diabetes [9, 12, 13], renal failure [9, 12, 13, 21], and having
prior high K+ values [12, 13, 21] to be significant predic-
tors of hyperkalaemia, we found hyperkalaemia incidence
rates to be higher among these patient populations. The
link between renal failure and diabetes with hyperkalaemia
in patients with heart failure is particularly well estab-
lished and we found the risk in diabetics to be relatively
constant over the duration of follow-up. Heart failure
patients are particularly vulnerable to the development of
hyperkalaemia when potassium excretion is already
impaired due to disease-related decline in glomerular
filtration, or circumstances, such as in diabetes, when
aldosterone production is decreased [4]. Furthermore,
most of these patients are on medications which block the
RAAS, such as ACE inhibitors, ARBs or aldosterone an-
tagonists. A comprehensive evaluation of hyperkalaemia
risk factors, including medications, has been published
recently [28].
Our study followed up a large cohort of patients from a
validated primary care database representative of the UK
population for up to 12 years [16]. It is based on real-life
data, reflecting actual practice in the primary care setting
as opposed to clinical trials where patients are closely
monitored for adverse events, such as hyperkalaemia.
Another strength of our study is the high proportion of
cases (99 %) that were ascertained using an operational
definition of hyperkalaemia based on laboratory data
(values of serum K+) thereby decreasing misclassification
in the assessment of hyperkalaemia episodes compared
with assessment based only on diagnostic codes [27]. Our
study also has limitations. It is possible that there was
some under-ascertainment of hyperkalaemia cases be-
cause the level of detection is largely dependent on the
level of awareness and monitoring by the PCP. Also,
although hyperkalaemia is a condition largely managed in
primary care, more severe cases are hospitalized and we
would rely on this information to be communicated back
to the PCP and recorded in the patient’s medical notes.
On the other hand, some selection bias towards more
severe patients may have occurred because patients with
greater comorbidity are more likely to be investigated.
The impact of any such potential selection bias, however,
is likely to be small because the majority of heart failure
patients (over 80 %) had at least one laboratory value of
serum K+ recorded.
Conclusions
To properly ascertain the incidence of hyperkalaemia in
patients with heart failure and thereby evaluate hyperka-
laemia risk and guide therapeutic decision making, it isimportant that a precise definition of the clinical event is
used. In addition, when different referral laboratories are
used in research studies, such as in primary care studies,
we propose that a proportional increase above the upper
bound of normal range in the corresponding laboratory
is used instead of a fixed absolute K+ value. Careful moni-
toring of serum K+ levels, particularly in more elderly
patients and in those with prior comorbidity such as
diabetes or renal impairment is recommended.
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